(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Reuters reported that President Trump’s tariffs have impacted the broader stock markets, weighing on investors’ sentiments, ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Gilead Sciences reported revenues of $7.57 billion, up 6.4% year on year. This print beat analysts’ expectations by 6.3%. It ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...